ARDS - Aridis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures4

Market Cap (intraday) 6.66M
Enterprise Value 7.91M
Trailing P/E 2.83
Forward P/E 1.61
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)5.40
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA -0.27

Trading Information

Stock Price History

Beta (5Y Monthly) N/A
52-Week Change 3-61.54%
S&P500 52-Week Change 30.07%
52 Week High 32.7700
52 Week Low 30.1500
50-Day Moving Average 30.2436
200-Day Moving Average 30.8322

Share Statistics

Avg Vol (3 month) 33.74M
Avg Vol (10 day) 318.12M
Shares Outstanding 536.08M
Implied Shares Outstanding 6N/A
Float 827.48M
% Held by Insiders 131.53%
% Held by Institutions 111.60%
Shares Short (May 14, 2023) 4756.18k
Short Ratio (May 14, 2023) 42.35
Short % of Float (May 14, 2023) 42.18%
Short % of Shares Outstanding (May 14, 2023) 42.10%
Shares Short (prior month Apr 13, 2023) 4573.28k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Dec 30, 2022


Profit Margin 0.00%
Operating Margin (ttm)-970.33%

Management Effectiveness

Return on Assets (ttm)-90.36%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)3.09M
Revenue Per Share (ttm)0.17
Quarterly Revenue Growth (yoy)22.90%
Gross Profit (ttm)-22.61M
EBITDA -29.51M
Net Income Avi to Common (ttm)-30.37M
Diluted EPS (ttm)-1.8300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.88M
Total Cash Per Share (mrq)0.14
Total Debt (mrq)6.13M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.31
Book Value Per Share (mrq)-0.90

Cash Flow Statement

Operating Cash Flow (ttm)-29.13M
Levered Free Cash Flow (ttm)-19.47M